Group 1 - The company has submitted an application for issuing H shares to the Hong Kong Stock Exchange, with the relevant filing materials accepted by the China Securities Regulatory Commission [1] - In the large chemical sector, the company aims to enhance its profitability by extending its upstream and downstream industrial chain, including several strategic investment projects in polystyrene production [1] - The company plans to actively promote the recovery of production capacity at Guoen Chemical (Dongming) and integrate internal resources to establish a complete vertical industrial chain from monomers to end products [1] Group 2 - In the health sector, the company is focusing on the "collagen+" strategy, with its subsidiary Dongbao Biological leading in the collagen field and expanding its hollow capsule production capacity [2] - Dongbao Biological has an annual production capacity of 13,500 tons of gelatin, while Yiqing Biological has a capacity of 39 billion hollow capsules, which is expected to increase significantly after the completion of its new production project [2] - The company anticipates a significant increase in performance due to the expansion of hollow capsule production capacity, entering a growth phase [2] Group 3 - The company expects to achieve net profits of 742 million, 947 million, and 1.095 billion yuan from 2025 to 2027, with corresponding price-to-earnings ratios of 12.57X, 9.84X, and 8.52X, respectively [2]
国恩股份(002768):深化“一体两翼”布局 业绩或进入放量期